SK3 Group's (OTC-PINK: SKTO) Medical Greens Is Pleased to Announce That the First Bottles of Dharmanol(TM) Are Shipping & Wil...
February 14 2014 - 10:50AM
Marketwired
SK3 Group's (OTC-PINK: SKTO) Medical Greens Is Pleased to Announce
That the First Bottles of Dharmanol(TM) Are Shipping and Will Be
Immediately Available on www.pharmajanes.com Among Other Places
LOS ANGELES, CA--(Marketwired - Feb 14, 2014) - SK3 Group, Inc's
(OTC Pink: SKTO) subsidiary Medical Greens is pleased to announce
that the first bottles of Dharmanol™ Whole Plant tablets, for
which Medical Greens has the exclusive license, are shipping
today. Dharmanol™ is a medical cannabis-based supplement that
contains all of the natural elements of the cannabis/hemp plant
that are thought to promote healing, with the exception of THC, the
molecule which is responsible for the psychoactive effect -- or
"high" -- of marijuana.
Dharmanol™, developed by David Hoye and Dr. Charles Apel of
Berkeley Bio-Organic Research Laboratories, contains under .03%
THC, less than many hemp-based health products that are sold at
stores such as Costco and Walgreens. But it contains 10 mg. of the
non-psychoactive phyto-cannabinoids that are present in
hemp/cannabis, and are thought to contribute to the myriad of
mechanisms that many university-level scientific studies have shown
to be responsible for the remarkable healing power of medical
marijuana.
Dharmanol™ tablets will be available soon in California through
AEGY's www.pharmajanes.com delivery service and select medicinal
marijuana dispensaries.
Dharmanol™ is sold in a bottle of 8 tablets. The suggested
retail price for a bottle is $25.00. Each tablet contains 5
mg. cannabidiol (CBD), 5 mg. of non-psychoactive mixed carboxylates
of the primary cannabinoids, 5 mg. of mixed separated terpenes and
terpenoids of cannabis/hemp, 25 mg. of organic cold-pressed hemp
oil, and 25 mg. of vitamin C (ascorbic acid as a preservative).
Dharmanol Citrolene™ will be released shortly. This formulation
combines the phyto-cannabinoid formula found in Dharmanol™ with a
substantial dose of the terpene d-Limonene. D-Limonene is found in
cannabis/hemp, but also present in the rinds of certain citrus
fruits. D-Limonene has been shown to bind with the same receptors
as benzodiazapines such as Valium and Xanax, producing a pronounced
relaxing and anti-spasmodic effect, without the negative side
effects that many attribute to the synthetic pharmaceuticals.
"We are pleased to be able to start delivering this important
product to market through our distribution network of dispensaries
and our related web-based delivery service www.pharmajanes.com,"
said Artemus Mayor, President of SK3 Group, Inc. "These
products are industry leading and will allow us to deliver the
health benefits of medical marijuana to more patients who will not
have to worry about feeling 'high' after their use. These
products will contribute directly to our topline revenue
growth."
FDA Statement The statements in this document have not been
evaluated or approved by the FDA. The products and statements
referenced in this document are not intended to diagnose, treat,
cure, or prevent any disease.
About SK3 SK3 is a healthcare logistics and fulfillment
consultancy focused on the delivery of alternative care and
medicine. With seasoned management, breakthrough technology and
best practices, SK3 brings standardization and transparency to this
rapidly growing segment of the alternative care field.
Safe Harbor Statement This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based on the
current plans and expectations of management and are subject to a
number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Medical Greens investors@medicalgreens.com Investor
Relations
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Apr 2024 to May 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From May 2023 to May 2024